{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-26-000042","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2026-08-05T20:07:48+00:00","discovered_at":"2026-08-05T20:09:00.248288+00:00","generated_at":"2026-08-05T20:10:50.722964+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Q2 net loss $91M, revenue $41M; casdatifan pipeline advances with new collaborations","bullets":["Net loss of $91M in Q2 2026 vs. $0 in Q2 2025; revenue fell to $41M from $160M.","Cash $775M at June 30; expects ~$600M year-end; runway to at least H2 2028.","Casdatifan: multiple data readouts H2 2026; new collaborations with BMS, Summit, AVEO.","Gilead relinquishes three board seats; PACIFIC-8 Phase 3 study discontinued.","Quemliclustat gets EU orphan drug designation; PRISM-1 Phase 3 results due H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-26-000042","json":"https://secwatch.observer/filing/0001724521-26-000042.json","markdown":"https://secwatch.observer/filing/0001724521-26-000042.md","text":"https://secwatch.observer/filing/0001724521-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/0001724521-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/rcus-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:10:50.722964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}